REGENXBIO to Participate in Upcoming Investor Conferences

Rhea-AI Summary

REGENXBIO (RGNX) has announced its participation in multiple upcoming investor conferences throughout May and June 2025. The company will be present at five major healthcare and biotech events:

- BofA Securities Health Care Conference in Las Vegas (May 13)
- RBC Global Healthcare Conference in New York (May 20)
- H.C. Wainwright BioConnect in New York (May 20)
- Stifel Virtual Ophthalmology Forum (May 27)
- UBS Spring Biotech Conference in New York (June 24)

Select presentations and fireside chats will be available via webcast on REGENXBIO's website, with recordings accessible for approximately 30 days after each event.

News Market Reaction

-18.85%

1 alert

-18.85% News Effect

On the day this news was published, RGNX declined 18.85%, reflecting a significant negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

ROCKVILLE, Md., May 6, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences:

BofA Securities Health Care Conference 2025
Presentation: Tuesday, May 13, 2025 at 5:00 p.m. PT
Location: Las Vegas, NV

RBC Global Healthcare Conference
Fireside Chat: Tuesday, May 20, 2025 at 11:30 a.m. ET
Location: New York, NY

H.C. Wainwright BioConnect
Fireside Chat: Tuesday, May 20, 2025 at 4:00 p.m. ET
Location: New York, NY

Stifel Virtual Ophthalmology Forum 
Fireside Chat: Tuesday, May 27, 2025 at 9:30 a.m. ET
Location: Virtual

UBS Spring Biotech Conference
1x1 Investor Meetings: Tuesday, June 24, 2025
Location: New York, NY

Live webcasts of select presentations and fireside chats can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.

ABOUT REGENXBIO Inc.
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM.

Contacts:

Dana Cormack
Corporate Communications
dcormack@regenxbio.com 

Investors:
George E. MacDougall
Investor Relations
IR@regenxbio.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-participate-in-upcoming-investor-conferences-302446818.html

SOURCE REGENXBIO Inc.

FAQ

What investor conferences will REGENXBIO (RGNX) attend in May and June 2025?

REGENXBIO will attend five conferences: BofA Securities Health Care Conference (May 13), RBC Global Healthcare Conference (May 20), H.C. Wainwright BioConnect (May 20), Stifel Virtual Ophthalmology Forum (May 27), and UBS Spring Biotech Conference (June 24).

Where can investors watch REGENXBIO's (RGNX) conference presentations?

Live webcasts of select presentations and fireside chats can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com, with recordings available for approximately 30 days after each presentation.

Which REGENXBIO (RGNX) conference presentations will be in New York?

Three conferences will be held in New York: the RBC Global Healthcare Conference, H.C. Wainwright BioConnect, and the UBS Spring Biotech Conference.

When is REGENXBIO's (RGNX) presentation at the BofA Securities Health Care Conference 2025?

REGENXBIO will present at the BofA Securities Health Care Conference in Las Vegas on Tuesday, May 13, 2025, at 5:00 p.m. PT.